Co-Diagnostics

Co-Diagnostics OCF/Debt

The Operating Cash Flow to Debt Ratio of Co-Diagnostics (CODX) as of Nov 20, 2026 is -2,356.29 %. In the previous year, Operating Cash Flow to Debt Ratio was -1,354.68 % — a change of 73.94% (lower).

OCF/Debt

-2,356.29 %

YoY

73.94%

Last updated:

Operating Cash Flow to Debt Ratio of Co-Diagnostics is 2025 -2,356.29 % . Operating Cash Flow to Debt Ratio of Co-Diagnostics was 2024 -1,354.68 % . It decreases by 73.94% lower compared to the previous year.

The Co-Diagnostics OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2015
-151.29 USD
Jan 1, 2016
-38.66 USD
Jan 1, 2018
-213.77 USD
Jan 1, 2021
676.49 USD
Jan 1, 2022
1,888.02 USD
Jan 1, 2023
-738.38 USD
Jan 1, 2024
-1,354.68 USD
Jan 1, 2025
-2,356.29 USD
The Co-Diagnostics OCF/Debt history
YEAROCF/DebtYoY
-2,356.29 %+73.94%
-1,354.68 %+83.46%
-738.38 %-139.11%
1,888.02 %+179.09%
676.49 %-416.45%
-213.77 %+452.91%
-38.66 %-74.44%
-151.29 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co-Diagnostics Stock analysis

What does Co-Diagnostics do? Co-Diagnostics, Inc. develops and sells diagnostic tests using proprietary reagents and a test design system for diseases and pathogens including tuberculosis, drug-resistant tuberculosis, hepatitis B and C, malaria, dengue, HIV, and Zika virus. The company also markets self-contained lab systems (MDx devices) from other manufacturers. Its products are sold to laboratories and healthcare providers for molecular testing of organisms and genetic diseases, automating complex procedures in test development and administration. The firm generates revenue through the sale of diagnostic reagents, validated tests, and MDx devices. The company's diagnostic technology focuses on nucleic acid detection and analysis, enabling molecular testing for various pathogens and genetic conditions. Its proprietary system allows for the design and validation of tests in-house, which are then marketed to healthcare institutions. Revenue streams include reagent sales, test kits, and equipment from partner manufacturers. Co-Diagnostics, Inc. targets laboratories and healthcare providers as key customers for its diagnostic solutions. The firm's products are designed to streamline molecular testing processes, reducing the complexity of traditional methods. This approach supports the company's revenue model based on direct sales of its proprietary tests and complementary equipment. Co-Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co-Diagnostics stock

Operating Cash Flow to Debt Ratio of Co-Diagnostics is -2,356.29 % in 2025.

Operating Cash Flow to Debt Ratio of Co-Diagnostics changed from -1,354.68 % to -2,356.29 %, representing a 73.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Co-Diagnostics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Co-Diagnostics

All Key Metrics — Co-Diagnostics